Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X4ZV
|
|||
| Former ID |
DIB007010
|
|||
| Drug Name |
BAX-499
|
|||
| Synonyms |
ARC-19499; Tissue factor pathway inhibitor (hemophilia A/hemophilia B), Archemix
Click to Show/Hide
|
|||
| Indication | Factor IX deficiency [ICD-11: 3B11; ICD-10: D67] | Phase 1 | [1] | |
| Company |
Archemix Corp
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue factor pathway inhibitor (TFPI) | Target Info | Inhibitor | [2], [3] |
| KEGG Pathway | Complement and coagulation cascades | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | Syndecan-4-mediated signaling events | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| Integrated Breast Cancer Pathway | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01191372) First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients. U.S. National Institutes of Health. | |||
| REF 2 | Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost. 2013 Jun;11(6):1137-45. | |||
| REF 3 | Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J Thromb Haemost. 2012 Aug;10(8):1581-90. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.